Smith & Nephew PLC

Chart & Performance

D1W1MN

P/E

81.03

P/S

3.84

EPS

0.30

Div Yield, %

1.53%

Shrs. gr., 5y

-12.99%

Rev. gr., 5y

2.50%

Revenues

5.55b

+6.40%

Net income

263m

+17.94%

CFO

608m

+29.91%

Dividend

Oct 04, 20240.273 USD/sh

Earnings

Feb 25, 2025

Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

URL

https://www.smith-nephew.com/

IPO date

Aug 13, 1951

Employees

19,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	5,549,000 6.40%	5,215,000 0.06%	5,212,000 14.30%
Cost of revenue	4,631,000	6,908,000	6,644,000
Unusual Expense (Income)
NOPBT	918,000	(1,693,000)	(1,432,000)
NOPBT Margin	16.54%
Operating Taxes	27,000	12,000	62,000
Tax Rate	2.94%
NOPAT	891,000	(1,705,000)	(1,494,000)
Net income	263,000 17.94%	223,000 -57.44%	524,000 16.96%
Dividends	(327,000)	(327,000)	(329,000)
Dividend yield			5.79%
Proceeds from repurchase of equity		(152,000)	59,000
BB yield			-1.04%
Debt
Debt current	765,000	160,000	491,000
Long-term debt	2,518,000	2,712,000	2,848,000
Deferred revenue		2,529,000	2,563,000
Other long-term liabilities	171,000	(2,565,000)	(2,707,000)
Net debt	2,957,000	2,464,000	1,851,000
Cash flow
Cash from operating activities	608,000	468,000	877,000
CAPEX	(427,000)	(358,000)	(408,000)
Cash from investing activities	(448,000)	(472,000)	(691,000)
Cash from financing activities	(200,000)	(926,000)	(645,000)
FCF	387,000	(2,104,000)	(1,501,000)
Balance
Cash	302,000	350,000	1,290,000
Long term investments	24,000	58,000	198,000
Excess cash	48,550	147,250	1,227,400
Stockholders' equity	4,696,000	5,201,000	5,402,000
Invested Capital	8,423,450	8,013,750	7,686,600
ROIC	10.84%
ROCE	10.82%
EV
Common stock shares outstanding	436,877	436,500	439,000
Price			12.94 -14.34%
Market cap			5,678,465 -14.24%
EV			7,857,465
EBITDA	1,445,000	(1,188,000)	(910,000)
EV/EBITDA
Interest	139,000	80,000	80,000
Interest/NOPBT	15.14%